Expert Insights

Mark Litzow, MD, presents findings from a phase 3 trial showing the addition of blinatumomab to consolidation chemotherapy improves overall survival in patients with newly diagnosed B-lineage ALL.

Srdan Verstovsek, MD, discusses the long-term safety of momelotinib in patients with high- and intermediate-risk myelofibrosis, using data from 3 randomized controlled trials: SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM.

Nicholas Short, MD, presents findings from an analysis exploring simultaneous ponatinib and blinatumomab treatment for patients with newly diagnosed Philadelphia chromosome-positive ALL.

Lucia Masarova, MD discusses findings from a phase 2 study showing long-term durability of responses and disease control with pegylated interferon in patients with essential thrombocythemia and polycythemia vera after 15 years.

Peter O’Donnell, MD, discusses an analysis from from the KEYNOTE-045 and KEYNOTE-052 trials, showing continued efficacy and safety of pembrolizumab for patients with metastatic urothelial carcinoma after 5 years of follow-up.

Talha Munir, MD, discusses findings from an updated interim analysis of the FLAIR study at the 2022 ASH Annual Meeting & Exposition in New Orleans, LA.

Christopher R. Flowers, MD, MD Anderson Cancer Center, Houston, TX discusses the results of the GO29365 study on polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma.

At the 2022 San Antonio Breast Cancer Symposium, Rachel Jimenez, MD, reviews updates and advancements in radiotherapy technology for patients with breast cancer.

At the 2022 San Antonio Breast Cancer Symposium, Per Karlsson, MD, PhD presents results from the meta-analysis investigating the prognostic value of POLAR scores in predicting the benefit of radiotherapy for patients with breast cancer.

At the 2022 San Antonio Breast Cancer Symposium, Aditya Bardia, MD, discusses the efficacy of elacestrant vs standard of care endocrine therapy for patients with ER-positive, HER2-negative, metastatic breast cancer by duration of prior...